Skip to main content
OpenTrials
Completed

NCT Number: NCT00556270

Efficacy of Matrifen in Patients Older Than 18 Years With Severe, Chronic Pain

The aim of the study is to evaluate the efficacy and safety of matrifen in patients with severe and chronic pain who can only be sufficiently treated with opioid analgesics (WHO class 3).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

"Nycomed Deutschland GmbH", Aachen, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Main inclusion criteria:

  • Patients with severe, chronic pain

Main exclusion criteria:

  • Hypersensitivity of fentanyl
  • Co-administration of monoaminooxidase-inhibitors
  • Pregnancy
  • Respiratory depression
  • Chronic obstructive pulmonary disease (COPD)
  • Drug abuse
  • Impairment of CNS functions
  • Other criteria as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.3)

Treatment and study plan

Matrifen

Drug

as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)

Primary outcomes

  1. Treatment success, efficacy of Matrifen

    Time frame: within 1 month

Secondary outcomes

  1. Safety and tolerability of fentanyl and the transdermal system, quality of life

    Time frame: within 1 month

Sponsors and collaborators

Lead sponsor

Nycomed

Industry

Registry information

Official study title

Matrifen for Therapy of Severe, Chronic Pain.

Acronym: MATRIX II

Important dates

Study start
2007
Study completion
2008
First posted
Nov 9, 2007
Registry last updated
May 7, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.